Abarceo Pharma
VerifiedDeveloping small molecule technology platform for the treatment of mitochondrial dysfunction, with an initial focus on T2D.
Launch date
Employees
Market cap
-
Net debt
-
Enterprise valuation
$10—16m (Dealroom.co estimates Mar 2021.)
Company register number 559139-7160
Malmö kommun Skane County (HQ)
| EUR | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (23 %) | (50 %) | - | - |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | $0.0 | round |
| investor | $0.0 | round | |
| investor | $0.0 | round | |
| investor | $0.0 | round | |
| N/A | $0.0 | round | |
| N/A | SEK22.0m | Seed | |
| Total Funding | 000k | ||
Related Content
Recent News about Abarceo Pharma
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.